Literature DB >> 12657172

Cavernous sinus exenteration for invasive cranial base tumors.

Bernard George1, Cristina Anastasia Ferrario, Alexandre Blanquet, Frédéric Kolb.   

Abstract

OBJECTIVE: Invasive tumors involving the cavernous sinus, such as recurrent benign meningiomas or sarcomas, raise therapeutic problems that may be resolved by cavernous sinus exenteration (CSE).
METHODS: Our series comprises 18 patients (9 women and 9 men ranging in age from 14 to 64 yr) who underwent CSE during the past 8 years. The tumors in these patients included 12 meningiomas, 3 chondrosarcomas, 1 rhabdomyosarcoma, 1 lipomyosarcoma, and 1 epidermoid carcinoma. Preoperative occlusion of the internal carotid artery was confirmed in 15 cases by a balloon occlusion test. Three patients had a negative balloon occlusion test, and their internal carotid arteries were preserved (n = 1) or revascularized (n = 2) through an external carotid artery-to-middle cerebral artery bypass.
RESULTS: CSE was performed as a primary treatment in 5 patients and after one to five recurrences in 13 patients. In all patients, CSE included the internal carotid artery and Cranial Nerves III, IV, and VI and one to three branches of Cranial Nerve V. Orbital exenteration was performed in eight patients, and partial hypophysectomy was performed in five patients. Ten patients had received radiotherapy before CSE, and five patients underwent irradiation after CSE. The operative mortality includes two patients. Cerebrospinal fluid leakage was the main complication in four patients, with three patients having meningitis. Follow-up ranged from 6 months to 5 years, with three deaths from new recurrences at 2, 3, and 4 years after CSE. As compared with their clinical courses before CSE, all patients except the two who died postoperatively benefited from CSE.
CONCLUSION: CSE has useful indications in invasive and rapidly growing tumors, including apparently benign meningiomas. A better understanding of the biological behavior of these tumors is necessary for appropriate selection of patients for CSE.

Entities:  

Mesh:

Year:  2003        PMID: 12657172     DOI: 10.1227/01.neu.0000053364.33375.c2

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Revascularization for complex skull base tumors.

Authors:  Jorge Mura; David Rojas-Zalazar; Evandro de Oliveira
Journal:  Skull Base       Date:  2005-02

2.  Cavernous Sinus Meningioma with Orbital Involvement: Algorithmic Decision-Making and Treatment Strategy.

Authors:  Amol Raheja; William T Couldwell
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-17

3.  Cranial chondrosarcoma and recurrence.

Authors:  Orin G Bloch; Brian J Jian; Isaac Yang; Seunggu J Han; Derick Aranda; Brian J Ahn; Andrew T Parsa
Journal:  Skull Base       Date:  2010-05

Review 4.  A systematic review of intracranial chondrosarcoma and survival.

Authors:  Orin G Bloch; Brian J Jian; Isaac Yang; Seunggu J Han; Derick Aranda; Brian J Ahn; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2009-09-30       Impact factor: 1.961

5.  Magnetic Resonance Angiography-based Prediction of the Results of Balloon Test Occlusion.

Authors:  Noriaki Fukuhara; Wataro Tsuruta; Hisayuki Hosoo; Masayuki Sato; Yuji Matsumaru; Mitsuo Yamaguchi-Okada; Masanori Yoshino; Takayuki Hara; Shozo Yamada; Hiroshi Nishioka
Journal:  Neurol Med Chir (Tokyo)       Date:  2019-07-27       Impact factor: 1.742

6.  Management of cavernous sinus meningiomas: Consensus statement on behalf of the EANS skull base section.

Authors:  Marco V Corniola; Pierre-Hugues Roche; Michaël Bruneau; Luigi M Cavallo; Roy T Daniel; Mahmoud Messerer; Sebastien Froelich; Paul A Gardner; Fred Gentili; Takeshi Kawase; Dimitrios Paraskevopoulos; Jean Régis; Henry W S Schroeder; Theodore H Schwartz; Marc Sindou; Jan F Cornelius; Marcos Tatagiba; Torstein R Meling
Journal:  Brain Spine       Date:  2022-01-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.